Nicola Davies, PhD

Nicola Davies, PhD, has a background in health psychology and over a decade of experience in medical writing. In addition to writing both US and EU regulatory columns, she has produced many large industry reports for the pharmaceutical industry. Topics she has covered range from orphan drugs to biosimilars, digital health, clinical trials, medical affairs, and payer perceptions, among many others. She also produces independent medical education for healthcare providers wishing to develop their knowledge of the pharmaceutical landscape.
Biosimilars have made headlines for their potential to offer a more affordable treatment option to patients in need of biologics. Today, with the increasing knowledge and identification of rare diseases, biosimilars have a renewed purpose in healthcare; they represent a significant opportunity to fulfill the unmet medical needs of rare disease patients at a much lower cost.
Nov 8, 2019 @01:41 PM

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.